NCT00453388View on ClinicalTrials.gov

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Acute Myeloid Leukemia in Remissionde Novo Myelodysplastic SyndromeFanconi AnemiaPreviously Treated Myelodysplastic Syndrome
Interventions
PROCEDURE

Allogeneic Bone Marrow Transplantation

Undergo allogeneic bone marrow transplant

DRUG

Cyclophosphamide

Given IV

DRUG

Cyclosporine

Given IV or PO

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Mycophenolate Mofetil

Given PO

PROCEDURE

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic stem cell transplant

RADIATION

Total-Body Irradiation

Undergo TBI

Trial Locations (5)

37232

Vanderbilt University/Ingram Cancer Center, Nashville

53201

Children's Hospital of Wisconsin, Milwaukee

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

94609-1809

Children's Hospital and Research Center at Oakland, Oakland

80060-000

Universidade Federal do Paraná, Curitiba

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00453388 - Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia | Biotech Hunter | Biotech Hunter